Medscape

PASCAL Mitral Valve Repair Shines at 2 Years in CLASP

Transcatheter mitral valve repair with the PASCAL device showed high rates of survival and freedom from heart failure rehospitalization at 2 years in the single-arm, safety and efficacy CLASP study.
Seeking Alpha

CLASP IID ONE-YEAR DATA CONFIRM SAFETY AND EFFICACY OF EDWARDS PASCAL SYSTEM FOR DEGENERATIVE MITRAL REGURGITATION

SAN FRANCISCO, Oct. 26, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) announced one-year results from CLASP IID, the first randomized controlled trial that directly compares two ...
Seeking Alpha

Edwards SAPIEN M3 Receives CE Mark, Becoming World’s First Transfemoral Transcatheter Mitral Valve Replacement System

IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences Corporation (EW) today announced the company’s SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter treatment of ...
TCTMD

PASCAL Implantation for Commissural Leaflet Prolapse With Severe Primary Mitral Regurgitation: Mimicking a Surgical “Magical Stitch” Procedure

Evoque Tricuspid Replacement in Patient With Multiple Leads Using Intracardiac Echocardiography Alone With the "Back-Bend" Technique Receive the the latest news, research, and presentations from major ...
Morningstar

FDA Approves Edwards Lifesciences' SAPIEN M3 Mitral Valve Replacement System as First Transseptal Transcatheter Therapy

Edwards Lifesciences (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system is the first transcatheter therapy utilizing a transseptal approach to receive U.S. Food and ...
TCTMD

TCT 1470: Amplatzer Vascular Plug II to Treat Residual Mitral Regurgitation After PASCAL Implantation

TCT 1857: Successful Coil Embolization of a Large Coronary Pseudoaneurysm After Repeated Drug‑Coated Balloon Angioplasty: A Complex Case Report Receive the the latest news, research, and presentations ...